Liberty Leaf - Wo Rauch ist, ist doch auch... (Seite 2)

eröffnet am 17.06.20 21:34:41 von
neuester Beitrag 20.01.21 08:31:00 von

Beitrag schreiben

Begriffe und/oder Benutzer



 Ja Nein
22.06.20 18:54:00
Antwort auf Beitrag Nr.: 64.131.253 von Boerseninsider-com am 22.06.20 18:48:01ja, ich bin auch optimistisch hier, wir werden sehen
Nova Mentis Life Science | 0,048 €
23.06.20 13:39:51
Antwort auf Beitrag Nr.: 64.131.253 von Boerseninsider-com am 22.06.20 18:48:01Habe das Gewehr ebenfalls im Anschlag

Denke, heute ist ein guter Kauftag

(keine Kauf oder Verkauf Empfehlung)
Nova Mentis Life Science | 0,041 €
23.06.20 16:06:40
Digging into $LIB's acquisition of Nova Mentis with Dr. Aylia Mohammadi

When deciding whether to invest in a junior stock or not, the first box to check is whether you have faith in management to execute their vision. Psychedelic medicine is a new, burgeoning sector, and having experienced, capable scientists on your team is a necessity. On June 22nd, Liberty Leaf (CSE:LIB) acquired Nova Mentis, a research company, spearheaded by Dr. Aylia Mohammadi, who has a PhD in Biological Physics. Today we spent two hours with Dr. Mohammadi, discussing the company’s aggressive plan to prove her hypothesis that the benefits of psilocybin do not just relate to mental health, but also, to the well-being of the body.

Why Nova Mentis is Different from the Rest

If you’ve read our previous articles, you’re likely aware that psilocybin was granted breakthrough status by the FDA in November, 2019, to fast-track tests for treatment of depression related mental health issues. In our Psilocybin Drug Profile , we noted how serotonin receptors in the brain worked to induce central nervous system effects on the body, however, the compound also interacts with serotonin receptors in the gut. To our knowledge, the vast majority of psilocybin research has been focused on the brain, but Dr. Mohammadi is taking a new approach, measuring the effects of psilocybin in the gut and the gut-brain axis . Ideally, through her research, Dr. Mohammadi intends to explore the anti-inflammatory effects of psilocybin to therapeutically target depression in individuals with comorbid obesity and diabetes.

A 2008 study published in the Journal of Pharmacology and Experimental Therapeutics demonstrated that the activation of the 5-HT(2A) serotonin receptor, which is one target of psychedelics such as psilocybin, produces a potent anti-inflammatory effect. This receptor behaves differently depending on where it is and what is attached, and to date has been studied primarily for its role in the brain. However this receptor is expressed in many tissues, including the gut. There are direct and indirect pathways of communication between the gut and the brain. The Vagus nerve, for example, connects the gut to the brain, working in both directions, sending messages, and receiving them. One research aim at Nova Mentis is to understand the therapeutic potential of activating these and other receptors with psilocybin in the “second brain” that lives in the gut, our enteric nervous system.

There is a reciprocal relationship between depression and obesity, since having one increases the risk of having the other. They often appear together as comorbidities. In the United States, 43% of depressed people are labelled as obese, while 30% of obese individuals experience depression. 27% of Canadians are labelled as obese, and 36% are considered overweight, based on BMI stats. Half of Canadians will experience at least one mental health related episode by the age of 40. Depending on the person, depression can change one’s appetite – some people eat less, and some eat more. The pro-inflammatory state may contribute to overeating while also driving insulin resistance. Psilocybin has therapeutic potential in a disease model that combines treatment of physiological issues with behavioural change. In addition to the anti-inflammatory qualities, anecdotal evidence of subjects taking various doses of psilocybin often report a lack of appetite. Therefore, micro-dosing psilocybin might not only solve depression related issues, but could also aid in the comorbidity issues of metabolic disorders.

Initial Test Plans

Each company’s research must be specific towards establishing a clear thesis, in order to prove a new drug’s efficacy, and save time bringing a new drug to market. Nova Mentis plans to run two concurrent tests, with the first preclinical experiments scheduled to take 3-5 months, aimed at determining the systemic anti-inflammatory effect of psilocybin with obesity and while measuring microbiome. The tests will aim to understand how psilocybin modulates the gut-brain axis and effects on metabolic and mental health. Dr. Mohammadi also will explore subjects of chronic low-grade inflammation, or systemic inflammation, investigating alterations in the microbiome and intestinal barrier function.

Final Thoughts

Throughout our conversation, Dr. Mohammadi’s passion and enthusiasm about her research was infectious and her objective moving forward is clear. The potential market for psilocybin might grow exponentially as a result of Mohammadi’s research to include a new segment for psilocybin therapy. If successful, Mohammadi’s research could prove the merits of microdosing psilocybin in appetite regulation, without hallucinogenic effects, while also solving mood altering effects through alterations in the microbiome.

We should also tell you, Dr. Mohammadi did mention the potential for her research to improve the psilocybin molecule for the purpose of improving the microdose outcome but she would not elaborate on this subject. If Mohammadi were able to achieve this feat, and her research proved her hypothesis, in 3-5 years, Liberty Leaf’s acquisition of Nova Mentis today on June 22nd will look like a genius move. For full disclosure, today we bought $LIB stock today, after our discussion with the doctor, and we look forward to bringing our readers future updates on her progress.

Stock Action

After Liberty Leaf’s announcement of the psilocybin deal, $LIB traded ten times its normal daily volume, and it seems many of the weak hands in the stock were shaken out into stronger hands, with smart money accumulating. We expect this trend to continue as the company begins to talk about its new future, and investors learn what we learned today. It is also important to note that it appears Nova Mentis will not face the same issue as Champignon’s failure to publish a Business Acquisition Report (BAR) as there were $6,584,935 in assets as of the last audited financials, so the acquisition would not exceed the asset threshold requirement.

Good fortune to all subscribers,
Mushroom Index Investor Team

86 Mining Services Inc, Torre A, Suite 1002, Torre De Las Americas,
Nova Mentis Life Science | 0,041 €
2 Antworten
24.06.20 09:49:19
Antwort auf Beitrag Nr.: 64.145.506 von Boerseninsider-com am 23.06.20 16:06:40Ein sehr interessanter Artikel!

Besten Dank für die Information
Nova Mentis Life Science | 0,041 €
1 Antwort
13.11.20 23:49:16
Antwort auf Beitrag Nr.: 64.155.121 von Aktien-Fan am 24.06.20 09:49:19Sieht in meinen Augen so aus, dass wieder Bewegung nach oben einsetzt.

Wäre nicht überrascht, wenn die Aktie bis Ende Jahr weiter Richtung Can 0.40 marschiert
Nova Mentis Life Science | 0,133 €
01.12.20 11:39:49
Mir gefällt die zuletzt getätigte Übernahme von Nova. Ich habe in den letzten Wochen in Kanada Stücke eingesammelt.

Ich bin gespannt wie sich die Aktie weiterentwickelt.
Nova Mentis Life Science | 0,171 €
1 Antwort
01.12.20 18:42:32
Antwort auf Beitrag Nr.: 65.902.647 von boersenreportpunktcom am 01.12.20 11:39:49Erachte ich auch so. Die Übernahme macht in meinen Augen Sinn.

Gerade im Gesundheitswesen bestehen wohl sehr grosse Chancen
Nova Mentis Life Science | 0,207 €
03.12.20 14:08:49
Nova Mentis Appoints Dr. Marvin S. Hausman as Chairman of Scientific Advisory Board
Canada NewsWire

VANCOUVER, BC, Dec. 3, 2020

VANCOUVER, BC, Dec. 3, 2020 /CNW/ - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) ("NOVA" or the "Company") is pleased to announce that it has appointed Dr. Marvin S. Hausman, MD as Chairman of its Scientific Advisory Board, effective immediately. Dr. Hausman is the Chief Medical Officer of Pilz Bioscience Corp., a wholly-owned subsidiary of NOVA and is leading their research and development efforts in medicinal psychedelics. Dr. Hausman is an immunologist and board-certified urological surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research and Axonyx.

Dr. Hausman's plan is to assemble an Advisory Board composed of scientific thought leaders who can help advance the newly emerging field of psilocybin therapeutics.

"I want to have a visibly active Scientific Advisory Board whose scientific knowledge is complementary, creative and furthers the development of our psychedelic medicines portfolio," says Dr. Hausman.

"Following our acquisition of Pilz Bioscience, the Board is privileged to have Dr. Hausman Chair the Scientific Advisory Board and provide guidance as we develop and advance our portfolio within the medicinal psychedelic sector," says Will Rascan, NOVA's President and CEO. "Given his successful career as a surgeon and biotech business leader, with expertise in drug commercialization, Dr. Hausman brings an impressive resume of success and a wealth of experience and passion to the NOVA team. We are excited and gratified to be working with him on our new journey."

Pursuant to a consulting agreement with Dr. Hausman, the Company has issued Dr. Hausman 250,000 common shares. The shares are subject to a hold period of four months and one day.

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Pilz Bioscience Corp., a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs, initially focussed on Autism Spectrum Disorder (ASD). - Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.

On Behalf of the Board

Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

SOURCE Nova Mentis Life Science Corp.

View original content:…
Nova Mentis Life Science | 0,192 €
12.01.21 09:56:43
auf watchlist

Tageschart mit bewegung...

Nova Mentis Life Science | 0,167 €
1 Antwort
20.01.21 08:31:00
Antwort auf Beitrag Nr.: 66.394.382 von eula am 12.01.21 09:56:43scheint auch ne neue website zu geben
Nova Mentis Life Science | 0,150 €

Beitrag zu dieser Diskussion schreiben

Liberty Leaf - Wo Rauch ist, ist doch auch...